Lobular neoplasia

Summary

Lobular neoplasia (MONDO:0002486) is a disease and 3 clinical trials. Top therapeutic interventions include narsoplimab and vemircopan. A subtype of breast carcinoma in situ — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	lobular neoplasia
Mondo ID	MONDO:0002486
DOID	DOID:3010
NCIT	C27939
UMLS	C0861352
MedGen	167824
Is cancer (heuristic)	no

Also known as: LIN · LN · lobular intraepithelial neoplasia · lobular neoplasia

Disease family

This is a subtype of breast carcinoma in situ. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › in situ carcinoma › breast carcinoma in situ › lobular neoplasia

Related subtypes (3): breast apocrine carcinoma in situ, ductal breast carcinoma in situ, ductal breast carcinoma in situ and lobular carcinoma in situ

Subtypes (2): atypical lobular breast hyperplasia, lobular breast carcinoma in situ

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02682407	PHASE2	TERMINATED	Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721
NCT05097989	PHASE2	TERMINATED	Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
NCT07203404	EARLY_PHASE1	RECRUITING	A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
NARSOPLIMAB	3	1
VEMIRCOPAN	2	1